Sanofi Could Be In Trouble For Lying To The Government About Their Zantac Cancer Knowlege
Heavily publicized tests of ranitidine started in 1982 that confirmed ranitidine was unstable and could become carcinogenic
Saturday, June 12, 2021 - Individuals that have filed lawsuits against Sanofi, GalaxoSmithKline, Boehringer, and other ranitidine manufacturers have focused their complaints on the fraud and negligence the companies allegedly committed by failing to warn their customers of the inherent instability of the ranitidine molecule. Visit Zantac antacid cancer lawsuit to learn more.
Not only have recent studies confirmed Valisure‘s accusations about ranitidine breaking down to form N-nitrosodimethylamine (NDMA) under conditions similar to the gastric conditions found inside the human body, but the original testing of ranitidine reached similar conclusions decades ago and were widely ignored.
A study titled ‘Analysis of ranitidine-associated N-Nitrosodimethylamine (NDMA) production under simulated physiologic conditions,‘ published in the Journal of the American Medical Association (JAMA), a January 2020 MedRxiv study called: ‘Ranitidine use, N-Nitrosodimethylamine (NDMA) production and variations in cancer diagnoses," and a 2008 study conducted at the Fred Hutchinson Cancer Research Center, all confirm that the ranitidine molecule itself breaks down to form NDMA when exposed to high temperatures or nitrites in the stomach, according to the Valisure blog.
Zantac cancer plaintiffs alleged the manufacturers of Zantac knew about the research linking ranitidine with NDMA decades ago. The U.S. Department of Justice (DOJ) has been investigating Sanofi for over a year and has accused Sanofi executives of lying to government regulators. In addition, Sanofi last month was accused of destroying evidence in the form of emails that could have led to a better understanding of what the company knew about Zantac NDMA and when they knew it. Bloomberg reported: "French drugmaker Sanofi destroyed internal emails tied to a 2019 recall of the heartburn medication Zantac, according to lawyers for more than 70,000 former patients who sued the company in the U.S."
Valisure‘s CEO David Light wrote: ‘Beyond Valisure‘s tests, the presence of NDMA in ranitidine is supported by decades of scientific studies at institutions around the world starting as early as 1982. The data published today adds to a growing body of research that raises serious concern regarding ranitidine and its potential to form the potent carcinogen NDMA."
Online prescription drug testing pharmacy Valisure alerted the FDA a few years ago that ranitidine, the active ingredient in Zantac heartburn and acid reflux medicine, was inherently unstable and could become carcinogenic. Valisure has since published a new website RanitidineInfo.com to share the latest scientific discoveries about the compound. The website‘s homepage begins, "The fundamental principle behind four decades of research and concern over ranitidine is its molecular instability and formation of the potent carcinogen, NDMA. "
More than 70000 individuals have indicated that they have developed cancer of the stomach, bladder, esophagus, and other cancer from taking Zantac regularly. Zantac was the best-selling brand of heartburn and acid reflux medicine for decades. The drug had about 15-million U.S. prescription and over-the-counter customers when it was recalled on April 1, 2020, over cancer fears. Experts think that Zantac cancer litigation could be one of the largest mass tort actions in US history alongside tobacco and asbestos.
